Journal article
A Gonococcal Vaccine Has the Potential to Rapidly Reduce the Incidence of Neisseria gonorrhoeae Infection among Urban Men Who Have Sex with Men
BB Hui, TN Padeniya, N Rebuli, RT Gray, JG Wood, B Donovan, Q Duan, R Guy, JS Hocking, MM Lahra, DA Lewis, DM Whiley, DG Regan, KL Seib
Journal of Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2022
Abstract
Background: A gonococcal vaccine is urgently needed due to increasing gonorrhea incidence and emerging multidrug-resistant gonococcal strains worldwide. Men who have sex with men (MSM) have among the highest incidences of gonorrhea and may be a key target population for vaccination when available. Methods: An individual-based, anatomical site-specific mathematical model was used to simulate Neisseria gonorrhoeae transmission in a population of 10000 MSM. The impact of vaccination on gonorrhea prevalence was assessed. Results: With a gonococcal vaccine of 100% or 50% protective efficacy, gonorrhea prevalence could be reduced by 94% or 62%, respectively, within 2 years if 30% of MSM are vaccin..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This study was supported by the National Institutes of Health (grant number U19 AI144182); and the National Health and Medical Research Council (grant number 1145642). The Kirby Institute is funded by the Australian Government Department of Health, and is affiliated with the Faculty of Medicine, University of New South Wales, Sydney, Australia.